Skip to main content
. Author manuscript; available in PMC: 2019 May 28.
Published in final edited form as: Leukemia. 2018 Feb 22;32(9):1932–1947. doi: 10.1038/s41375-018-0062-8

Fig. 2.

Fig. 2

Decreased expression of immune checkpoints in myeloma patients’ bone marrow mononuclear cells with ACY241 treatment. The expression levels of immune checkpoints were evaluated following treatment of myeloma patients’ bone marrow mononuclear cells with ACY241 (0, 0.5, 1 μM; 48 h). ACY241 treatment decreased PD-L1 expression on CD138+ MM cells (Fig. 2a) and regulatory T cells (Fig. 2b) as well as PD-1 expression on CD8+ Tc (Fig. 2c) in a dose-dependent manner (p < 0.05)